Chengda Pharmaceutical (301201.SZ) : Sales of pharmaceutical intermediates customized for Pfizer accounted for a smaller proportion of revenue

2022-06-15 0 By

Zhitong Financial APP news, Chengda Pharmaceutical (301201.SZ) announced that the company’s stock on February 14, February 15 in two consecutive trading days closing price rise deviation value accumulated more than 30%, according to the “Shenzhen Stock Exchange gem trading special provisions”, belongs to the abnormal stock trading fluctuations.The company noted recent investor interest in its pharmaceutical intermediates business in the media and on interactive platforms, in particular whether the company’s pharmaceutical intermediates are used in Pfizer novel Coronavirus specific drugs.Here is an explanation of the relevant situation:The company is mainly committed to providing key pharmaceutical intermediates CDMO services for multinational pharmaceutical enterprises and pharmaceutical RESEARCH and development institutions. Entrusted by Pfizer API factory, the company customized research and development of pharmaceutical intermediates PF-07304814. The corresponding sales revenue from January to June in 2020 and 2021 accounted for 0.61% and 1.16% of the operating revenue respectively.The sales revenue of this part accounts for a small proportion of the company’s operating revenue and has not had a significant impact on the company’s performance.After verification, the company, the controlling shareholder and the actual controller do not have any major matters about the company that should be disclosed but have not been disclosed, nor any major matters in the planning stage.